RAIN: Machine Learning-based identification for HIV-1 bNAbs

Mathilde Foglierini^{1,2,3,*}, Pauline Nortier^{1,2,*}, Rachel Schelling^{1,2}, Rahel R. Winiger^{1,2}, Philippe Jacquet⁴, Sijy O'Dell⁵, Davide Demurtas⁶, Maxmillian Mpina⁷, Omar Lweno⁷, Yannick D. Muller^{1,2}, Constantinos Petrovas⁸, Claudia Daubenberger^{9,10}, Mathieu Perreau¹, Nicole A Doria-Rose⁵, Raphael Gottardo³ and Laurent Perez^{1,2,#}

¹Department of Medicine, Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

²Centre for Human Immunology Lausanne, Switzerland.

³Biomedical Data Science Centre, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

⁴Scientific Computing and Research Support Unit, University of Lausanne, Lausanne, Switzerland.

⁵Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

⁶Interdisciplinary center of electron microscopy, CIME, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.

⁷Ifakara Health Institute, Bagamoyo, United Republic of Tanzania.

⁸Department of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne

University Hospital, Lausanne, Switzerland

⁹Department of Medical Parasitology and Infection Biology, Clinical Immunology Unit,

Swiss Tropical and Public Health Institute, Basel, Switzerland.

¹⁰University of Basel, Basel, Switzerland.

*These authors contributed equally

#Corresponding author: Laurent Perez

email: laurent.perez@chuv.ch

Supplementary Information

Supplementary Figures 1-10 Supplementary Tables 1-3



Supplementary Figure. 1. Correlation of each feature pair in the dataset against the class distribution.

Pairwise relationships between the specific features comparing mAbs (blue) and bNAbs (red). Each bNAb category is represented by a single plot per antigenic site: (a) CD4bs, (b) MPER, (c) V1V2 apex, (d) V3 glycan, and (e) gp120/gp41 interface. Source data are provided as a Source Data file.



Supplementary Figure 2. Determination of the epsilon parameter for the Anomaly detection algorithm. Epsilon parameters for the antigenic site (a) CD4bs, (b) MPER, (c) V1V2 apex, (d) V3 glycan, and (e) gp120/gp41 interface. The accuracy is in red and the area under the curve (AUC) is in blue.



Supplementary Figure 3. Random Forest classifier with only two features. Left panels are the decision regions obtained from the training dataset and right panels are the receiver-operating characteristic (ROC) curves in orange with the corresponding area under the curve (AUC). The dashed blue line is for visual reference. Statistics are visualized for the different antigenic sites: (a) V1V2 apex, (b) gp120/gp41 interface, (c) CD4bs, (d) MPER, and (e) V3 glycan.



Supplementary Figure 4. Determination of the cost complexity pruning parameter alpha (ccp_alpha) for the Decision Tree classifier. Targeted antigenic sites are (a) CD4bs, (b) MPER, (c) V1V2 apex, (d) V3 glycan, and (e) gp120/gp41 interface.



Supplementary Figure 5. Overlap of false and true positives between the three different models using the test datasets. Venn diagrams and Confusion matrices for each model are represented next to the Venn diagram. Antigenic sites are (a) CD4bs, (b) MPER, (c) V1V2 apex, (d) V3 glycan, and (e) gp120/gp41 interface. The yellow circle represents AD, the blue one is DT, and the red one is RF. Source data are provided as a Source Data file.

| | | | | | J/C | mac | y scall | ision |
|-----------|----|----|------|----|------|-------|---------|-------|
| _ | TP | FP | TN | FN | Ac | Accur | Rec | recr |
| CD4bs | 8 | 0 | 3739 | 7 | 0.77 | 1.00 | 0.53 | 1.00 |
| MPER | 5 | 0 | 3740 | 1 | 0.92 | 1.00 | 0.83 | 1.00 |
| V1V2 | 11 | 0 | 3753 | 1 | 0.96 | 1.00 | 0.92 | 1.00 |
| V3 | 6 | 0 | 3738 | 11 | 0.68 | 1.00 | 0.35 | 1.00 |
| Interface | 7 | 0 | 3739 | 1 | 0.94 | 1.00 | 0.88 | 1.00 |



CD4bs **MPER** 1.0 1.0 True Positive Rate 0.8 0.8 0.6 0.6 0.4 0.4 0.2 0.2 AUC = 0.77 AUC = 0.92 0.0 0.0 0.6 0.8 0.8 0.2 0.4 1.0 0.0 0.2 0.4 0.6 1.0 0.0 V1V2 apex V3 glycan 1.0 1.0 True Positive Rate 0.8 0.8 0.6 0.6 0.4 0.4 0.2 0.2 AUC = 0.96 AUC = 0.68 0.0 0.0 0.0 0.2 0.4 0.6 0.8 1.0 0.0 0.2 0.4 0.6 0.8 1.0 False Positive Rate Interface 1.0 True Positive Rate 0.8 0.6 0.4 0.2 AUC = 0.94 0.0 0.0 0.2 0.4 0.6 0.8 1.0 False Positive Rate

Supplementary Figure 6. Performance and results of the Super Learner Ensembles algorithm. (a) Performance metrics of the algorithm using the test dataset with Accuracy = (TP+TN) / (TP+FP+TN+FN), Recall = TP / (TP+FN), and Precision = TP / (TP+FP). (b) Receiver-operating characteristic (ROC) curves and corresponding area under the curve (AUC) statistics for each bNAb antigenic site with the test dataset.

b





140

120

100

80

60 40

20

0

Supplementary Figure 7. Predicted bNAbs per dataset. (a) The heatmap illustrates the number of predicted bNAbs for each antigenic site and each run of donors using various algorithms, with D1: donor 1, D2: donor 2 (donor that did not have sera with broad neutralization activity) and B3, G3, S4, G4: donor 3 (donor serum with broad neutralization activity). The G5, G6, and G7 datasets correspond to a Influenza-specific repertoire. The columns on the right side of the heatmap show bNAbs identified by different algorithms. The abbreviations used in each cell represent the combination of algorithms that share the specific bNAbs (AD/DT: bNAbs predicted only by both AD and DT, AD/RF: bNAbs predicted only by both AD and RF, DT/RF: bNAbs predicted only by both DT and RF and AD/DT/RF: bNAbs predicted by all AD, DT and RF). (b) The heatmap illustrates the number of predicted bNAbs for each antigenic site and each run of donors using the Super Learner (SL) algorithm. The columns on the right side of the heatmap show bNAbs shared by different algorithms. The abbreviations used in each cell represent the combination of algorithms that share the specific bNAbs (SL/DT: bNAbs predicted only by both SL and DT, SL/DT/RF: bNAbs predicted only by SL, DT and RF and SL/AD/DT/RF: bNAbs predicted by all SL, AD, DT and RF).

b

| а | FR1 | CDR1 | FR2 | CDR2 | FR | 3 | CDR3 | FR4 |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|----------------------------------------------------|------------|
| | 1 2 2 0 2 2 0 1 1 0 2 1 2 0 2 1 2 0 2 1 2 0 2 2 0 2 2 0 2 2 0 2 2 0 2 2 0 2 2 2 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 | 12 0 12 13 7 7 | 4 4 0 | 50 55 60 60 | ∞ ∩ √ 0 8 √ √ 0 | 0 2 CBB | 95 100A 100A 100C 100C 100C 100C | 105 |
| UCA | QVQLVQSGAEVKKPGASVKVS | S C K A S G Y T F T <mark>G Y Y M H</mark> W V R | QAPGQGLEWMO | G <mark>W I N P N S G G T N Y A</mark> | <mark>Q K F Q G</mark> R V T M T R D T S I S T A Y M E L | SRLRSDDTAVYYCAX | <mark>x x x x x x x x x x x x x x x </mark> v | GQGTLVTVSS |
| VRC01 | | RE.I <mark>DCTLN</mark> .I. | LKRP | LK.RG.AV | RPL | RS.TVF.TR | GKNCDYNWDFEH. | RP.I |
| bNAb4251 | HVMDQQ | TTSS.I <mark>EDSL.</mark> .IQ | .VEPL | V R H . A V S | <mark>W.IRD</mark> .II.KM.VQM | RG.QMK | SRRGANWAL. | .WRI |
| bNAb2101 | VMDQ.RER | T.EDV <mark>ES.L.</mark> | EPLA | ARN.AV | <mark>- Slrd</mark> .l.lIYV.VDM | RG.Q | ARRGNTWAFR. | .WRI |
| bNAb1586 | .E.PPSL | RGDENL.I <mark>EI.</mark> .I. | н. | MSILT.APS | <mark>GN.RN</mark> .MS.YRD. | RG.T | SRRRSGRGGTWQFQ. | |
| b | FR1 | CDR1 | FR2 | CDR2 | FR3 | CDR3 | FR4 | |
| | 1 1 20 | | 40 | 202 202 | | | | |
| UCA | DIQMTQSPSSLSASVGDRVT | | RPGKAPKLLI | Y DASNLETGVPSR | FSGSGSGTDFTFTISSLQPEDI | | GGGTRVEIK | |
| bNAb4251 | L Y . A | RE.NDL. | RP | SG | .R.SSLG | G | R.D | |
| bNAb2101 | . L . LD | RDR | P | K . DR | ALNT.E.D.F | · · · · · · · · · · · · Q F · · | · · · · · D · · · | |
| bNAb1586 | | <mark>РG.Q.Q</mark> .н | R | G . R R | R.SL.NN | | R | |
| С | FR1 | CDR1 | FR2 | CDR2 | FR3 | CDR3 | FR4 | |
| UCA VRC0 | Image: Solution of the second secon | 50 6 90 LSCRASQSVSSYLAWYQQ ITYGS | 9 40 QKPGQAPRLLI . R | G G G G G G G G G G G G G G G G G G G | % % % % % FSGSGSGTDFTLTISSLEPED % % % % | 8 8 8 FAVYYC QQX XX F | GQGTKVQVD | |

Supplementary Figure 8. bNAbs alignment of VH and VK amino acid sequences. Upper panel: (a) Alignment of the VH sequence of the three predicted bNAbs with their UCA (unmutated common ancestor) and VRC01 bNAb. UCA is constituted of VH1-2*02 and JH4*02, the D gene is masked and represented by X. Residue positions are according to Kabat numbering. Dots indicate identical residues. (b) Middle panel: alignment of the VK sequences of the three predicted bNAbs with their UCA (unmutated common ancestor). UCA is constituted of VK1-33*01 and JK4*01, the LCDR3 is masked and represented by X. (c) Lower panel: alignment of the VK sequence of the VRC01 with its UCA VK3-11*01 and JK2*01.



Supplementary Figure 9. Antibodies and Fabs interaction with BG505-DS-SOSIP.

(a) Bivalent analyte fitting for antibody SOSIP interactions with concentrations ranging from 5 to 400 nM.
(b) Fitting of Fab interaction with BG505-DS-SOSIP using 1:1 model. For Fabs, concentrations ranging from 50 to 400 nM were used. Source data are provided as a Source Data file.



Supplementary Figure 10. Cryo-EM data processing and validation of Fab-BG505-DS-SOSIP complexes.

(a) Representative cryo-EM micrograph, 2D class average images and data processing flow chart.

(b) Local resolution of the final map and Gold standard Fourier shell correlation (FSC) at 0.143 resolution of 3.8 Å.

- (c) Angular distribution of the Fab-BG505-DS-SOSIP particles in the final round of 3D refinement.
- (d) Diferent density maps shown at threshold of 6 σ for VHVL, gp41 and gp120, respectively.

Supplementary Table 1. Source of the ten datasets used as mAbs in the machine learning models and the three datasets used as Influenza repertoires.

| | Paired BCRs | Deference | | | |
|-----|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|
| | (IGK/L+IGH) | Kelerence | | | |
| H1 | 4 581 | ArrayExpress: E-MTAB-11174 (Memory B cells of donor 1) | | | |
| H2 | 4 740 | ArrayExpress: E-MTAB-11174 (Memory B cells of donor 2) | | | |
| H3 | 965 | SRA: SRR17717616 | | | |
| H4 | 903 | SRA: SRR17717597 | | | |
| H5 | 895 | SRA: SRR17717612 | | | |
| H6 | 413 | SRA: SRR17717605 | | | |
| H7 | 341 | SRA: SRR17717601 | | | |
| H8 | 786 | SRA: SRR17717593 | | | |
| H9 | 429 | 10X dataset: 10k Human PBMCs, 5' v2.0, Chromium Controller, Single Cell Immune Profiling Dataset by Cell Ranger 6.1.0 (2021, August 9) | | | |
| H10 | 909 | 10X dataset: Human PBMC from a Healthy Donor, 10k cells (v2), Single Cell Immune Profiling Dataset by Cell Ranger 5.0.0 (2020, November 19) | | | |
| G5 | 4 691 | BioSample SAMN07733010, Day 9 after influenza vaccination. SRA : SRR10596386, SRR10596375, SRR10596364, SRR10596353 | | | |
| G6 | 8 222 | BioSample SAMN07733010, Day 7 after influenza vaccination. SRA : SRR10596411, SRR10596412, SRR10596410, SRR10596409 | | | |
| G7 | 8 052 | BioSample SAMN07733010, Day 7 after influenza vaccination. SRA : SRR10596407, SRR10596406, SRR10596405, SRR10596404 | | | |

| Algo | Ag site | bNAbs Numbers | ΤР | FP | TN | FN | AUC | Accuracy | Recall | Precision |
|------|-----------|------------------|----|----|------|----|------|----------|--------|-----------|
| AD | CD4bs | 15 | 12 | 22 | 2966 | 3 | 0.90 | 0.99 | 0.80 | 0.35 |
| DT | CD4bs | 15 | 7 | 4 | 2984 | 8 | 0.73 | 1.00 | 0.47 | 0.64 |
| RF | CD4bs | 15 | 7 | 0 | 2988 | 8 | 0.90 | 1.00 | 0.47 | 1.00 |
| AD | MPER | 3 | 1 | 38 | 2956 | 2 | 0.66 | 0.99 | 0.33 | 0.03 |
| DT | MPER | 3 | 2 | 4 | 2990 | 1 | 0.83 | 1.00 | 0.67 | 0.33 |
| RF | MPER | 3 | 2 | 0 | 2994 | 1 | 0.83 | 1.00 | 0.67 | 1.00 |
| AD | V1V2 apex | 25 | 19 | 55 | 2932 | 6 | 0.87 | 0.98 | 0.76 | 0.26 |
| DT | V1V2 apex | 25 | 23 | 12 | 2975 | 2 | 0.96 | 1.00 | 0.92 | 0.66 |
| RF | V1V2 apex | 25 | 19 | 0 | 2987 | 6 | 1.00 | 1.00 | 0.76 | 1.00 |
| AD | V3 glycan | 9 | 5 | 57 | 2938 | 4 | 0.77 | 0.98 | 0.56 | 0.08 |
| DT | V3 glycan | 9 | 6 | 8 | 2987 | 3 | 0.83 | 1.00 | 0.67 | 0.43 |
| RF | V3 glycan | 9 | 2 | 0 | 2995 | 7 | 1.00 | 1.00 | 0.22 | 1.00 |
| AD | Interface | 3 | 1 | 31 | 2964 | 2 | 0.66 | 0.99 | 0.33 | 0.03 |
| DT | Interface | 3 | 3 | 4 | 2991 | 0 | 1.00 | 1.00 | 1.00 | 0.43 |
| RF | Interface | 3 | 2 | 0 | 2995 | 1 | 1.00 | 1.00 | 0.67 | 1.00 |

Supplementary Table 2. Performance metrics of the three algorithms using the validation dataset.

| Data Accession PDB ID: 8S2E EMDB: EMD-19665 | | | | |
|---------------------------------------------|--------------|--|--|--|
| Magnification | 165'000 | | | |
| Voltage (kV) | 300 | | | |
| Electron exposure $(e - / Å^2)$ | 39.89 | | | |
| Defocus range (µm) | -0.9 to -2.4 | | | |
| Pixel size (Å) | 0.73277 | | | |
| Symmetry imposed | C1 | | | |
| Micrographs collected (no.) | 15,163 | | | |
| Final particle images (no.) | 72497 | | | |
| Map resolution (Å) | 3.8 | | | |
| FSC threshold | 0.143 | | | |
| Map resolution range (Å) | | | | |
| Refinement | | | | |
| Initial model used (PDB code) | 4TVP | | | |
| Model resolution (Å) | 3.8 | | | |
| FSC threshold | 0.143 | | | |
| Map sharpening B factor (Å ²) | | | | |
| Model composition | | | | |
| Non-hydrogen atoms | 16305 | | | |
| Protein residues | 1958 | | | |
| Ligands | BMA:6 | | | |
| C | NAG:73 | | | |
| | MAN:6 | | | |
| <i>B</i> factors (Å ²) | | | | |
| Protein | 100.6 | | | |
| R.m.s. deviations | | | | |
| Bond lengths (Å) | 0 | | | |
| Bond angles (°) | 0.75 | | | |
| Validation | | | | |
| MolProbity score | 2.10 | | | |
| Clashscore | 9.0 | | | |
| Poor rotamers (%) | 2.3 | | | |
| Ramachandran plot | | | | |
| Favored (%) | 95.5 | | | |
| Allowed (%) | 4.5 | | | |
| Disallowed (%) | 0.0 | | | |

Supplementary Table 3. Cryo-EM data collection, refinement, and validation statistics.